This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Abraham Zangen, PhD
Professor Abraham Zangen is the Head of the Brain Stimulation and Behavior Lab and the Chair of the PsychoBiology Brain Program at Ben-Gurion University in Israel.His research is directed at identifying and understanding altered neuroplasticity in psychiatric disorders – primarily depression, addiction and ADHD.
He studies the effects of repeated brain stimulation on markers for neuroplasticity and on behavioral outcomes in animal models for depression and addiction, as well as in psychiatric patients. He has developed with Dr. Yiftach Roth unique deep transcranial magnetic stimulation coils for the treatments of depression, addiction, OCD and ADHD.
The technology he and Dr. Roth has developed for the treatment of depression was already approved by the FDA and other regulatory bodies, while other versions of the coils they have developed are being tested for their efficacy in other psychiatric and neurological disorders.
His early work in this field led to the establishment of Brainsway, a company that commercializes the technologies he developed with his colleagues.
Prof. Zangen has published over 150 peer reviewed articles, reviews and book chapters.
He was rewarded with numerous personal prizes for his scientific achievements, including the Medical Futures Innovation Award in London, the Sieratzki Prize for Advances in Neuroscience and the Juludan Prize at the Technion, and he has received several distinguished research grants including NIH, H2020 and ISF funding.